ADC Therapeutics SA Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- ADC Therapeutics SA price/book ratio for the quarter ending 2026-06-30 was -0.59, a change of 0.93 year-over-year.
- ADC Therapeutics SA price/book ratio for the quarter ending 2026-03-31 was -2.2, a change of -1.61 year-over-year.
- ADC Therapeutics SA price/book ratio for the quarter ending 2025-12-31 was -2.39, a change of -1.42 year-over-year.
- ADC Therapeutics SA price/book ratio for the quarter ending 2025-09-30 was -1.9, a change of -0.12 year-over-year.
- ADC Therapeutics SA price/book ratio for fiscal 2026 was -0.59.
- ADC Therapeutics SA price/book ratio for fiscal 2025 was -2.39, a change of -1.42 from fiscal 2024.
- ADC Therapeutics SA price/book ratio for fiscal 2024 was -0.97, a change of -0.05 from fiscal 2023.
- ADC Therapeutics SA price/book ratio for fiscal 2023 was -0.92, a 123.64% decline from fiscal 2022.
- Available history
- 2021-12-31 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |